Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Microb Pathog ; 78: 52-62, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25433242

ABSTRACT

Inadequate and delayed antibiotic treatment of extended spectrum beta-lactamase (ESBL)-producing isolates have been associated with increased mortality of affected patients. The purpose of this study was to compare the host response of human renal epithelial cells and polymorphonuclear leucocyte (PMN) cells when infected by ESBL-producing uropathogenic Escherichia coli (UPEC) isolates in the presence or absence of ineffective antibiotics. The renal epithelial cell line A498 and PMN cells were stimulated with ESBL-producing UPEC isolates in the presence or absence of three different antibiotics (trimetoprim, ceftibuten and ciprofloxacin). Host cell responses were evaluated as release of cytokines (IL-6, IL-8), reactive oxygen species (ROS), ATP and endotoxins. Bacterial morphology and PMN phagocytosis were evaluated by microscopy. In the presence of ceftibuten, 2 out of 3 examined ESBL-isolates changed their morphology into a filamentous form. The presence of ceftibuten enhanced IL-6, IL-8 and ROS-production from host cells, but only from cells stimulated by the filamentous isolates. The bacterial supernatant and not the filamentous bacteria per se was responsible for the increased release of IL-6, IL-8 and ROS. Increased endotoxin and ATP levels were found in the bacterial supernatants from filamentous isolates. Apyrase decreased IL-6 secretion from A498 cells and polymyxin B abolished the increased ROS-production from PMN cells. PMN were able to inhibit the bacterial growth of some ESBL-isolates in the presence of ceftibuten. In conclusion, antibiotic-induced filamentation of ESBL-producing UPEC isolates and the associated release of ATP and endotoxins can alter the host cell response in the urinary tract.


Subject(s)
Anti-Bacterial Agents/pharmacology , Cephalosporins/pharmacology , Escherichia coli Infections/metabolism , Uropathogenic Escherichia coli/drug effects , Uropathogenic Escherichia coli/growth & development , beta-Lactamases/metabolism , Adenosine Triphosphate/metabolism , Ceftibuten , Cell Line , Escherichia coli Infections/genetics , Escherichia coli Infections/microbiology , Escherichia coli Proteins/genetics , Escherichia coli Proteins/metabolism , Humans , Interleukin-6/genetics , Interleukin-6/metabolism , Interleukin-8/genetics , Interleukin-8/metabolism , Reactive Oxygen Species/metabolism , Uropathogenic Escherichia coli/enzymology , Uropathogenic Escherichia coli/genetics , beta-Lactamases/genetics
2.
APMIS ; 122(11): 1136-43, 2014 Nov.
Article in English | MEDLINE | ID: mdl-24735173

ABSTRACT

The emergence of extended-spectrum ß-lactamase (ESBL)-producing Enterobacteriaceae is a major global concern. CTX-M is the dominating ESBL type worldwide, and CTX-M-15 is the most widespread CTX-M type. The dissemination of CTX-M appears to be in part due to global spread of the Escherichia coli clone O25b-ST131. However, the gene-encoding CTX-M is mainly located on mobile genetic elements, such as plasmids, that also promote the horizontal dissemination of the CTX-M genes. In this study, 152 CTX-M-producing E. coli isolated in 1999-2008 in Örebro County, Sweden, were typed using a commercial repetitive sequence-based PCR (the DiversiLab system), and the prevalence of ST131 was investigated by pabB PCR. Real-time PCR-based plasmid replicon typing was performed on 82 CTX-M-15-producing E. coli isolates. In general, the CTX-M-producing E. coli population was genetically diverse; however, ST131 was highly prevalent (27%), and the dominating clone in our area. The blaCTX -M-15 gene was mainly located on IncF plasmids (69%), but a relatively high proportion of IncI1 plasmids (29%) were also detected among E. coli with diverse rep-PCR patterns, indicating that horizontal transmission of IncI1 plasmids carrying blaCTX -M-15 may have occurred between different E. coli strains.


Subject(s)
Escherichia coli/genetics , Plasmids/genetics , Repetitive Sequences, Nucleic Acid/genetics , Replicon/genetics , Real-Time Polymerase Chain Reaction/methods , Sweden , beta-Lactamases/genetics
3.
BMC Microbiol ; 14: 65, 2014 Mar 14.
Article in English | MEDLINE | ID: mdl-24629000

ABSTRACT

BACKGROUND: Nitric oxide (NO) is produced as part of the host immune response to bacterial infections, including urinary tract infections. The enzyme flavohemoglobin, coded by the hmp gene, is involved in protecting bacterial cells from the toxic effects of NO and represents a potentially interesting target for development of novel treatment concepts against resistant uropathogenic bacteria. The aim of the present study was to investigate if the in vitro antibacterial effects of NO can be enhanced by pharmacological modulation of the enzyme flavohemoglobin. RESULTS: Four clinical isolates of multidrug-resistant extended-spectrum ß-lactamase (ESBL)-producing uropathogenic E. coli were included in the study. It was shown that the NO-donor substance DETA/NO, but not inactivated DETA/NO, caused an initial growth inhibition with regrowth noted after 8 h of exposure. An hmp-deficient strain showed a prolonged growth inhibition in response to DETA/NO compared to the wild type. The imidazole antibiotic miconazole, that has been shown to inhibit bacterial flavohemoglobin activity, prolonged the DETA/NO-evoked growth inhibition. When miconazole was combined with polymyxin B nonapeptide (PMBN), in order to increase the bacterial wall permeability, DETA/NO caused a prolonged bacteriostatic response that lasted for up to 24 h. CONCLUSION: An NO-donor in combination with miconazole and PMBN showed enhanced antimicrobial effects and proved effective against multidrug-resistant ESBL-producing uropathogenic E. coli.


Subject(s)
Anti-Bacterial Agents/pharmacology , Dihydropteridine Reductase/metabolism , Escherichia coli Proteins/metabolism , Hemeproteins/metabolism , Miconazole/pharmacology , NADH, NADPH Oxidoreductases/metabolism , Nitric Oxide/pharmacology , Polymyxin B/analogs & derivatives , Uropathogenic Escherichia coli/drug effects , Drug Synergism , Humans , Microbial Sensitivity Tests , Nanoparticles/metabolism , Polymyxin B/pharmacology , Uropathogenic Escherichia coli/enzymology , Uropathogenic Escherichia coli/growth & development , beta-Lactamases/metabolism
4.
Microb Pathog ; 66: 29-35, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24361394

ABSTRACT

Carbon monoxide (CO) releasing molecules (CO-RMs) have been shown to inhibit growth of commensal Escherichia coli (E. coli). In the present study we examined the effect of CORM-2 on uropathogenic E. coli (UPEC) that produces extended-spectrum ß-lactamase (ESBL). Viability experiments showed that CORM-2 inhibited the growth of several different ESBL-producing UPEC isolates and that 500 µM CORM-2 had a bactericidal effect within 4 h. The bactericidal effect of CORM-2 was significantly more pronounced than the effect of the antibiotic nitrofurantoin. CORM-2 demonstrated a low level of cytotoxicity in eukaryotic cells (human bladder epithelial cell line 5637) at the concentrations and time-points where the antibacterial effect was obtained. Real-time RT-PCR studies of different virulence genes showed that the expression of capsule group II kpsMT II and serum resistance traT was reduced and that some genes encoding iron acquisition systems were altered by CORM-2. Our results demonstrate that CORM-2 has a fast bactericidal effect against multiresistant ESBL-producing UPEC isolates, and also identify some putative UPEC virulence factors as targets for CORM-2. CO-RMs may be candidate drugs for further studies in the field of finding new therapeutic approaches for treatment of uropathogenic ESBLproducing E. coli.


Subject(s)
Anti-Bacterial Agents/pharmacology , Organometallic Compounds/pharmacology , Uropathogenic Escherichia coli/drug effects , beta-Lactamases/metabolism , ATP-Binding Cassette Transporters/metabolism , Adult , Bacterial Outer Membrane Proteins/metabolism , Cell Line , Cell Survival/drug effects , Culture Media/chemistry , DNA, Bacterial/genetics , Drug Resistance, Multiple, Bacterial , Epithelial Cells/drug effects , Escherichia coli Proteins/metabolism , Female , Gene Expression Regulation, Bacterial , Humans , Membrane Transport Proteins/metabolism , Microbial Viability/drug effects , Middle Aged , Nitrofurantoin/pharmacology , Urinary Bladder/cytology , Urine/microbiology , Uropathogenic Escherichia coli/enzymology , Virulence Factors/metabolism
5.
BMC Microbiol ; 13: 181, 2013 Aug 02.
Article in English | MEDLINE | ID: mdl-24059789

ABSTRACT

BACKGROUND: Infections caused by extended spectrum beta-lactamases (ESBL)-producing bacteria have been emerging worldwide and the majority of ESBL-producing E. coli strains are isolated from patients with urinary tracts infections. The purpose of this study was to compare the host-response mechanisms in human polymorphonucleated leukocytes (PMN) and renal epithelial cells when stimulated by ESBL- or non-ESBL-producing uropathogenic E. coli (UPEC) isolates. The host-pathogen interaction of these ESBL-producing strains in the urinary tract is not well studied. RESULTS: The ability of ESBL strains to evoke ROS-production from PMN cells was significantly higher than that of the non-ESBL strains. The growth of ESBL strains was slightly suppressed in the presence of PMN compared to non-ESBL strains after 30 min and 2h, but the opposite was observed after 5 and 6h. The number of migrating PMN was significantly higher in response to ESBL strains compared to non-ESBL strains. Stimulation of A498 cells with ESBL strains elicited lower production of IL-6 and IL-8 compared to non-ESBL strains. CONCLUSION: Significant differences in host-response mechanisms were identified when host cells were stimulated by ESBL- or non-ESBL producing strains. The obtained results on the early interactions of ESBL-producing strains with the host immune system may provide valuable information for management of these infections.


Subject(s)
Escherichia coli Infections/immunology , Escherichia coli Infections/microbiology , Urinary Tract Infections/immunology , Urinary Tract Infections/microbiology , Uropathogenic Escherichia coli/enzymology , beta-Lactamases/metabolism , Cells, Cultured , Host-Pathogen Interactions , Humans , Neutrophils/immunology , Neutrophils/microbiology , Reactive Oxygen Species/immunology , Uropathogenic Escherichia coli/classification , Uropathogenic Escherichia coli/immunology , Uropathogenic Escherichia coli/isolation & purification , beta-Lactamases/genetics
6.
APMIS ; 119(4-5): 287-95, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21492229

ABSTRACT

During the last decade increasing prevalence of extended-spectrum ß-lactamase (ESBL)-producing Enterobacteriaceae has been detected worldwide, mainly due to dissemination of Escherichia coli and Klebsiella pneumoniae producing CTX-M-type ESBLs. CTX-M-15 is the most widespread CTX-M type, and the predominant type in various countries. Dissemination of ESBL-producing organisms is caused not only by horizontal transfer of plasmids, but also by clonal spread of ESBL-producing strains. In this study, the molecular epidemiology of class A ESBL (ESBL(A))-producing E. coli and K. pneumoniae isolated in Örebro County, Sweden, was investigated. Out of 200 ESBL(A) -producing E. coli and K. pneumoniae isolates, collected over a 10-year period, 87% were producing CTX-M, belonging to subgroup CTX-M-1 (64%), CTX-M-9 (34%), or CTX-M-2 (2%). The remaining isolates were producing variants of SHV and TEM. Sequencing of the bla(CTX-M) genes revealed 10 different CTX-M types, with a dominance of CTX-M-15 (E. coli 54%, K. pneumoniae 50%) followed by CTX-M-14 (E. coli 28%, K. pneumoniae 27%). Phenotypic characterization of the CTX-M-producing isolates was performed using the PhenePlate system. Although a few minor clusters of CTX-M-15 and CTX-M-14 producers were identified, the majority of the isolates did not appear to be clonally related.


Subject(s)
Escherichia coli Infections/microbiology , Escherichia coli/enzymology , Escherichia coli/genetics , Klebsiella Infections/microbiology , Klebsiella pneumoniae/enzymology , Klebsiella pneumoniae/genetics , beta-Lactamases/biosynthesis , beta-Lactamases/genetics , Base Sequence , DNA Primers/genetics , DNA, Bacterial/genetics , Endemic Diseases , Escherichia coli/classification , Escherichia coli/isolation & purification , Escherichia coli Infections/epidemiology , Genes, Bacterial , Humans , Klebsiella Infections/epidemiology , Klebsiella pneumoniae/classification , Klebsiella pneumoniae/isolation & purification , Molecular Epidemiology , Phenotype , Phylogeny , Sweden/epidemiology , beta-Lactamases/classification
SELECTION OF CITATIONS
SEARCH DETAIL
...